On March 2, 2017 Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, reported data presentations relating to its technology platforms to be given at the Keystone Symposia on Cancer Immunology and Immunotherapy Conference: Taking a Place in Mainstream taking place in Whistler, B.C., Canada, March 19 through 23, 2017 (Press release, Aduro Biotech, MAR 2, 2017, View Source [SID1234517967]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster 1061: Administration of the synthetic STING agonist ADU-S100 leads to durable anti-tumor immunity via promoting T-cell responses
Poster Session: 1
Date/Time: Monday, March 20, 7:30 p.m. to 10:00 p.m. PT

Poster 2038: Efficacy of pLADD, a personalized immunotherapy strategy targeting tumor-specific neoantigens using live attenuated Listeria monocytogenes
Poster Session: 2
Date/Time: Tuesday, March 21, 2017, 7:30 p.m. to 10:00 p.m. PT